My following two posts are long because I’m trying to establish that Ryoncil is about a lot more than acute GvHD, the lead candidate of a precious acute platform. They're from the perspective of medical insurers who have a direct window onto the real world. I think this must be the most cynical jaded group who are surely aware that for a long time they’ve been paying out for marketing over substance.
IMO, it’s about more than acute GvHD. I’m looking mainly for evidence of Ryoncil as a prophylactic for chronic GvHD but beyond that.
We live in a world where the picture painted by statistics often doesn’t match reality. Please be aware the second post contains distressing details about chronic GVHD.
I have no doubt of a bad situation n IBD, especially pediatrics. I’m not advocating pestering doctors but if you get the opportunity to speak to a colorectal surgeon, ask them about the incidence of colectomies/resections since the advent of the “revolutionary” biologics.
- Forums
- ASX - By Stock
- MSB
- Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-553
-
-
- There are more pages in this discussion • 527 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.12 |
Change
-0.020(1.75%) |
Mkt cap ! $1.307B |
Open | High | Low | Value | Volume |
$1.14 | $1.17 | $1.11 | $4.746M | 4.158M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
17 | 81194 | $1.12 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.12 | 41549 | 14 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
17 | 81194 | 1.115 |
24 | 208925 | 1.110 |
21 | 190022 | 1.105 |
22 | 402466 | 1.100 |
5 | 43492 | 1.095 |
Price($) | Vol. | No. |
---|---|---|
1.120 | 39873 | 13 |
1.125 | 80051 | 13 |
1.130 | 67682 | 14 |
1.135 | 123995 | 12 |
1.140 | 128504 | 9 |
Last trade - 12.47pm 19/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
INF
INFINITY LITHIUM CORPORATION LIMITED
Ryan Parkin, Managing Director & CEO
Ryan Parkin
Managing Director & CEO
Previous Video
Next Video
SPONSORED BY The Market Online